Synthesis and Activity of T-Cell Tumor-Directing MegaMolecules

This paper describes the synthesis, characterization, and functional activity of 26 MegaMolecule-based bispecific antibody mimics for T-cell redirection toward HER2+ cancer cells. The work reports functional bispecific MegaMolecules that bind both receptor targets, and recruit and activate T-cells resulting in lysis of the target tumor cells. Changing the orientation of linkage between Fabs against either HER2 or CD3ε results in an approximately 150-fold range in potency. Increasing scaffold valency from Fab dimers up to tetramers improves the potency of the antibody mimics up to 5-fold, but with diminishing returns in effective dose beyond trimeric formats. Antibody mimics that present either one or two Fabs against either receptor target allows for initial engagement of one cell type over the other. Finally, the antibody mimics significantly reduce HER2+ tumor volumes in a humanized xenograft model of breast cancer.

Authors

Institutions

Publication Details

Journal
Journal of the American Chemical Society
Published
2024-08-21
DOI
https://doi.org/10.1021/jacs.4c07377
Citations
5
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
2.02

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Synthesis and Activity of T-Cell Tumor-Directing MegaMolecules

Eric J. Berns, Justin A. Modica, Milan Mrksich, Daniel J. Sykora et al.
5 citations
Journal of the American Chemical Society
Monoclonal and Polyclonal Antibodies Research
2.02
article

Synthesis and Activity of T-Cell Tumor-Directing MegaMolecules

Eric J. Berns, Justin A. Modica, Milan Mrksich, Daniel J. Sykora, Sraeyes Sridhar
article en
5 citations

Abstract

This paper describes the synthesis, characterization, and functional activity of 26 MegaMolecule-based bispecific antibody mimics for T-cell redirection toward HER2+ cancer cells. The work reports functional bispecific MegaMolecules that bind both receptor targets, and recruit and activate T-cells resulting in lysis of the target tumor cells. Changing the orientation of linkage between Fabs against either HER2 or CD3ε results in an approximately 150-fold range in potency. Increasing scaffold valency from Fab dimers up to tetramers improves the potency of the antibody mimics up to 5-fold, but with diminishing returns in effective dose beyond trimeric formats. Antibody mimics that present either one or two Fabs against either receptor target allows for initial engagement of one cell type over the other. Finally, the antibody mimics significantly reduce HER2+ tumor volumes in a humanized xenograft model of breast cancer.

Journal of the American Chemical SocietyVol. 146(39)
Northwestern University (US)
Northwestern University, Defense Threat Reduction Agency, Robert H. Lurie Comprehensive Cancer Center
Zero hunger
Openalex Percentile: Top 13%
Monoclonal and Polyclonal Antibodies Research
2.02
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Synthesis and Activity of T-Cell Tumor-Directing MegaMolecules — Eric J. Berns, Justin A. Modica, et al. · Journal of the American Chemical Society (2024) | TGRS Research Map | TGRS